News and Announcements
Charter Hall appoints David Harrison as CEO and MD
- Published February 01, 2016 4:05PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
1st February 2016, ASX Announcement
Charter Hall Group (ASX: CHC) (Charter Hall or the Group) today announced that David Harrison has been appointed Chief Executive Officer and Managing Director (CEO/MD) of the Group, with David Southon electing to step down as Joint Managing Director (JMD) following the Board and JMDs’ decision to move to a single CEO/MD structure.
Charter Hall Chair, David Clarke, confirmed the Board and JMDs have been working towards transitioning to a single CEO/MD structure over the past nine months as part of their focus on succession planning and building a strong leadership team for the Group.
“Ensuring the Group has the right senior leadership capability and structure to support its future plans has been a key focus for the Board and JMDs over the past three years. Given the Group’s significant growth, the work undertaken by the JMDs on building the leadership team through a number of key appointments and in positioning the business for the future, we believe now is the appropriate time to move to the single cEO/MD structure,” Mr Clarke said.
David Harrison will assume the CEO/MD role immediately, with founder David Southon to be available to the business for up to 12 months to facilitate a smooth handover and assist with the transition to the CEO/MD structure.
To read the full announcement, please click here.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
